Abbott Laboratories Reports Weak Earnings but Promising Growth Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy ABT?
Source: NASDAQ.COM
- Earnings Performance: Abbott's fourth-quarter revenue increased by only 4.4% year-over-year to $11.5 billion, primarily dragged down by weak performances in its diagnostic and nutrition segments, indicating challenges in sales growth in these areas.
- Medical Device Growth: Despite the overall disappointing results, Abbott's medical device segment generated $5.7 billion in revenue in the fourth quarter, reflecting a 12.3% year-over-year increase, suggesting that this division remains a core growth engine with potential to drive overall performance recovery.
- Acquisition Opportunity: Abbott announced its acquisition of cancer diagnostic company Exact Sciences for approximately $21 billion, which will bolster its diagnostic business, particularly with the Cologuard product that has significant potential in the U.S. market, where over 55 million eligible patients remain unscreened, presenting a vast market opportunity.
- Dividend Appeal: Abbott's forward yield exceeds 2.3%, surpassing the S&P 500's average of 1.2%, and with 54 consecutive years of dividend increases, it has earned the title of 'Dividend King', making its stock still attractive for income-seeking investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 95.470
Low
136.00
Averages
148.11
High
169.00
Current: 95.470
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Advances Multi-Biomarker Cancer Detection Technology
- Multi-Biomarker Detection: Abbott's new data indicates that the multi-cancer early detection (MCED) approach, which combines methylation and protein biomarkers, significantly enhances cancer detection accuracy, particularly in early stages, supporting the commercial Cancerguard® test.
- DETECT-A Study Outcomes: The AACR will present the Cancer Prevention Research Award recognizing the multi-year outcomes from the DETECT-A study, which showed that after a median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free, highlighting the clinical impact of MCED.
- Signal Analysis: In a prospectively collected case-control study, 47.1% of positive cancer signals were driven by methylation alone, 7.4% from protein-only, and 45.5% from combined biomarker signals, demonstrating the broad detection capabilities of MCED across various cancer types and stages.
- Future Screening Potential: Abbott's Chief Medical Officer Tom Beer stated that the long-term follow-up of MCED provides critical insights into the future of cancer screening, especially as nearly 70% of cancer types lack recommended screening, suggesting that MCED could significantly increase early detection rates and improve patient outcomes.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Abbott Unveils New Data on Multi-Cancer Early Detection at AACR 2026
- Multi-Biomarker Advantage: Abbott's Cancerguard® test enhances cancer detection accuracy by combining methylation and protein biomarkers, with data showing that 47.1% of positive signals were driven solely by methylation, indicating broad applicability across various cancer types and stages.
- Clinical Research Outcomes: The DETECT-A study's multi-year results reveal that after a median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free, underscoring the clinical impact of multi-cancer early detection and earning the AACR Cancer Prevention Research Award.
- Innovative Detection Method: Cancerguard is the first commercially available MCED test utilizing a multi-biomarker approach, integrating two classes of biomarkers to enhance detection capabilities, and in early-stage disease, many cancer signals were detected by a single biomarker class, showcasing its unique contributions.
- Future Screening Potential: With nearly 70% of cancers occurring in types without recommended screening, the findings from MCED research highlight its potential to increase early detection and improve patient outcomes, potentially transforming the future landscape of cancer screening.
See More
Market Preview: Oil Prices Drop, iPhone Shipments Surge
- Oil Price Decline: Oil prices fell approximately 10% after Iran declared the Strait of Hormuz open for commercial traffic during a 10-day ceasefire between Israel and Lebanon, which could negatively impact the earnings of related energy companies.
- Surge in iPhone Shipments: According to CounterPoint Research, iPhone shipments in China increased by 20% in Q1, despite an overall decline in the smartphone market due to soaring memory costs, providing a positive outlook for Apple's primary revenue source.
- Netflix Price Target Cuts: Barclays lowered Netflix's price target from $115 to $110, with Wolfe Research and Rosenblatt also cutting theirs to $107 and $95 respectively, leading to a more than 9% drop in shares, reflecting market concerns about its future performance.
- Target Price Adjustments: Several companies, including Danaher and Abbott Laboratories, saw their price targets cut, with Danaher's target reduced from $220 to $205 due to concerns over its legacy business, while Abbott's target was lowered to $120 by multiple firms, although all maintained a buy rating.
See More
ABBOTT: RAYMOND JAMES LOWERS TARGET PRICE FROM $130 TO $115
- Price Cut Announcement: Raymond James has reduced its target price for a specific stock from $130 to $115.
- Market Impact: This adjustment may influence investor sentiment and trading activity related to the stock in question.
See More
Abbott Laboratories Q1 Earnings Highlights
- Adjusted EPS Performance: Abbott Laboratories reported an adjusted earnings per share of $1.15 for Q1, aligning with guidance despite earlier-than-expected financing costs and a weaker respiratory season, demonstrating the company's resilience under challenging conditions.
- Medical Devices Sales Growth: The Medical Devices segment saw an 8.5% sales increase, driven by strong performance in cardiovascular devices, with double-digit growth in electrophysiology and heart failure products, indicating the company's market leadership in critical areas.
- Cancer Diagnostics Expansion: Cancer diagnostics sales grew by 13% year-over-year, with the acquisition of Exact Sciences expected to add approximately $3 billion in sales by 2026, further solidifying Abbott's competitive edge in cancer detection.
- Market Challenges and Outlook: Despite a 10% decline in sales for rapid and molecular diagnostics due to reduced demand for respiratory virus testing, Abbott remains optimistic about growth in the second half of the year, planning to leverage strategic initiatives in nutrition, electrophysiology, and core lab diagnostics to drive performance.
See More
Abbott Advances Multi-Biomarker Cancer Detection Technology
- Multi-Biomarker Detection: Abbott's new data indicates that the multi-cancer early detection (MCED) approach, which combines methylation and protein biomarkers, significantly enhances cancer detection accuracy, particularly in early stages, supporting the commercial Cancerguard® test.
- DETECT-A Study Outcomes: The AACR will present the Cancer Prevention Research Award recognizing the multi-year outcomes from the DETECT-A study, which showed that after a median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free, highlighting the clinical impact of MCED.
- Signal Analysis: In a prospectively collected case-control study, 47.1% of positive cancer signals were driven by methylation alone, 7.4% from protein-only, and 45.5% from combined biomarker signals, demonstrating the broad detection capabilities of MCED across various cancer types and stages.
- Future Screening Potential: Abbott's Chief Medical Officer Tom Beer stated that the long-term follow-up of MCED provides critical insights into the future of cancer screening, especially as nearly 70% of cancer types lack recommended screening, suggesting that MCED could significantly increase early detection rates and improve patient outcomes.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Abbott Unveils New Data on Multi-Cancer Early Detection at AACR 2026
- Multi-Biomarker Advantage: Abbott's Cancerguard® test enhances cancer detection accuracy by combining methylation and protein biomarkers, with data showing that 47.1% of positive signals were driven solely by methylation, indicating broad applicability across various cancer types and stages.
- Clinical Research Outcomes: The DETECT-A study's multi-year results reveal that after a median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free, underscoring the clinical impact of multi-cancer early detection and earning the AACR Cancer Prevention Research Award.
- Innovative Detection Method: Cancerguard is the first commercially available MCED test utilizing a multi-biomarker approach, integrating two classes of biomarkers to enhance detection capabilities, and in early-stage disease, many cancer signals were detected by a single biomarker class, showcasing its unique contributions.
- Future Screening Potential: With nearly 70% of cancers occurring in types without recommended screening, the findings from MCED research highlight its potential to increase early detection and improve patient outcomes, potentially transforming the future landscape of cancer screening.
See More
Market Preview: Oil Prices Drop, iPhone Shipments Surge
- Oil Price Decline: Oil prices fell approximately 10% after Iran declared the Strait of Hormuz open for commercial traffic during a 10-day ceasefire between Israel and Lebanon, which could negatively impact the earnings of related energy companies.
- Surge in iPhone Shipments: According to CounterPoint Research, iPhone shipments in China increased by 20% in Q1, despite an overall decline in the smartphone market due to soaring memory costs, providing a positive outlook for Apple's primary revenue source.
- Netflix Price Target Cuts: Barclays lowered Netflix's price target from $115 to $110, with Wolfe Research and Rosenblatt also cutting theirs to $107 and $95 respectively, leading to a more than 9% drop in shares, reflecting market concerns about its future performance.
- Target Price Adjustments: Several companies, including Danaher and Abbott Laboratories, saw their price targets cut, with Danaher's target reduced from $220 to $205 due to concerns over its legacy business, while Abbott's target was lowered to $120 by multiple firms, although all maintained a buy rating.
See More
ABBOTT: RAYMOND JAMES LOWERS TARGET PRICE FROM $130 TO $115
- Price Cut Announcement: Raymond James has reduced its target price for a specific stock from $130 to $115.
- Market Impact: This adjustment may influence investor sentiment and trading activity related to the stock in question.
See More
Abbott Laboratories Q1 Earnings Highlights
- Adjusted EPS Performance: Abbott Laboratories reported an adjusted earnings per share of $1.15 for Q1, aligning with guidance despite earlier-than-expected financing costs and a weaker respiratory season, demonstrating the company's resilience under challenging conditions.
- Medical Devices Sales Growth: The Medical Devices segment saw an 8.5% sales increase, driven by strong performance in cardiovascular devices, with double-digit growth in electrophysiology and heart failure products, indicating the company's market leadership in critical areas.
- Cancer Diagnostics Expansion: Cancer diagnostics sales grew by 13% year-over-year, with the acquisition of Exact Sciences expected to add approximately $3 billion in sales by 2026, further solidifying Abbott's competitive edge in cancer detection.
- Market Challenges and Outlook: Despite a 10% decline in sales for rapid and molecular diagnostics due to reduced demand for respiratory virus testing, Abbott remains optimistic about growth in the second half of the year, planning to leverage strategic initiatives in nutrition, electrophysiology, and core lab diagnostics to drive performance.
See More
